key: cord-0786629-cd4sou1z authors: Citi, Valentina; Martelli, Alma; Brancaleone, Vincenzo; Brogi, Simone; Gojon, Gabriel; Montanaro, Rosangela; Morales, Guillermo; Testai, Lara; Calderone, Vincenzo title: Anti‐inflammatory and antiviral roles of hydrogen sulfide: rationale for considering H(2)S‐donors in COVID‐19 therapy date: 2020-08-11 journal: Br J Pharmacol DOI: 10.1111/bph.15230 sha: 507f63f1e8f6f2c53bfc6ddf8720c9e8acb0c8fc doc_id: 786629 cord_uid: cd4sou1z The COVID‐19 pandemic caused by new betacoronavirus SARS‐Cov‐2 demands rapid exploration of safe and effective therapeutic options. In this perspective, “drug repurposing” aims to represent a rapid and valuable strategy. In the last decades, the endogenous gasotransmitter hydrogen sulfide (H(2)S) has emerged as a ubiquitous modulator of several biological functions. Early studies pointed out its importance in the regulation of numerous biological functions and systems. Accordingly, H(2)S deficiency has been associated with several disorders, and many chemotypes of H(2)S‐releasing agents have been developed as potential therapeutic tools for diseases related with impaired H(2)S production/activity. Some of these compounds are in advanced clinical trials. Presently, the pivotal role of H(2)S in modulating the inflammatory response and proinflammatory cytokine cascade is well recognized, and the usefulness of some H(2)S‐donors for the treatment of different forms of acute lung inflammation (due to infectious and non‐infectious etiologies) has been reported. More recent evidence is also unravelling several mechanisms of action which may account for antiviral effects of this gasotransmitter. Noteworthy, some preliminary clinical results suggest an inverse relationship between endogenous H(2)S levels and severity of COVID‐19 disease. Therefore, repurposing of H(2)S‐releasing drugs may be worthy of investigation as potential therapeutic opportunities for treatment of COVID‐19 disease. In this paper, the pharmacological basis for a potential role of H2S against COVID-19 and the potential repurposing of H2S-donor drugs in the management of this disease are discussed. Abe and Kimura first discovered that H2S is endogenously produced and is endowed with relevant physiological roles (Abe and Kimura, 1996) . Thereafter, H2S was recognized as the third gasotransmitter, after carbon monoxide (CO) and NO, and its biosynthesis and metabolism pathways were widely investigated (Martelli et al., 2012) . In mammalian cells, H2S is produced by non-enzymatic and enzymatic routes (Yang et al., 2019) . Cystathionine γ-lyase (CSE) and cystathionine β-synthase (CBS), which act within the "trans-sulfuration pathway", are the main H2S biosynthesizing enzymes (Pan et al., 2012; Miles and Kraus, 2004) . A further biosynthetic pathway involves the tandem cooperation of cysteine aminotransferase (CAT) and 3-mercaptopyruvate sulfurtransferase (3-MST) (Beltowski, 2019). A major source of H2S production in the brain derives from 3-MST which is localized into neuronal cytosol and mitochondria. 3-MST produces H2S and bound sulfane sulfur more efficiently than CBS, which was previously believed to be the only H2S-producing enzyme in the central nervous system. Furthermore, 3MST-CAT pathway produces polysulfides as well as H2S; in particular, levels of polysulfides measured as bound sulfane sulfur were more than twice greater in 3-MST overexpressing cells than control cells (Shibuya et al. 2009; Kimura et al. 2017) . Regarding the degradation of H2S, several pathways have been described. H2S is a reducing agent and thus can be oxidized by several circulating oxidants. However, one of the main H2S catabolism pathways operates in the mitochondria, leading to the formation of thiosulfate which is then converted by rhodanase enzyme into sulfite and finally sulfate. In addition, H2S can be methylated through S-methyltransferase (TSMT) with the formation of dimethylsulfide. Finally, H2S interacts with hemoglobin to produce sulfhemoglobin (Guo et al., 2013) . S-sulfhydration, a post-translational modification of cysteine residues of several target proteins, is considered the most plausible molecular mechanism for the H2S pleiotropic effects (Banerjee, 2011; Meng et al., 2018) . Noteworthy, H2S coexists in biological systems with sulfane sulfur species. They are heterogeneous compounds containing a reactive, labile sulfur atom which is covalently bonded to other sulfur atoms or to a sulfur and a hydrogen atom to form reactive sulfur compounds, including persulfides, polysulfides and some forms of elemental sulfur (Iciek et al., 2019; Toohey, 2011) . Sulfane sulfur species can be viewed as a form of "H2S storage", to maintain a low-grade toxicity and to allow gasotransmitter release in response to biological signals (Ishigami et al. 2009; Toohey, 2011) . Furthermore, sulfane sulfur species may act themselves through S-sulfhydration and therefore may be largely responsible for those biological activities attributed to H2S (Toohey, 2012) . Indeed, it has been demonstrated that alterations in sulfane sulfur levels reflect some patho-physiological conditions related to H2S-altered biosynthesis, strongly suggesting the close reciprocal relationships. Although intense research activity has been carried out, many roles of H2S in the homeostatic regulation of different systems and in the pathogenesis of several disorders have been elucidated, some mechanisms and pathways of H2S signalling are not yet completely understood. Since defective H2S endogenous production has been associated with many systemic disorders, great efforts have been directed to the development of effective pharmacological agents able to increase H2S levels. The pharmacological modulation of H2S is a dynamic field in recent drug discovery research, which has been well examined and reported in some seminal reviews (Szabo and Papapetropoulos, 2017; Zheng et al., 2018; Gojon and Morales, 2020) . Presently, a large number of natural and synthetic compounds have been recognized as effective H2S donors (Sardu et al., 2020; Keyaerts et al., 2004) and some of them are in clinical trials for the treatment of cardiovascular diseases (e.g., SG-1002 for heart favourable outcome display levels of the gasotrasmitter higher than those found in patients with severe COVID-19 pneumonia. This evidence suggests that the reduction of H2S bioavailability may be considered as an indicator of enhanced proinflammatory response and that the administration of exogenous H2S may be viewed as a pharmacological strategy to restore H2S plasma levels in order to counteract the severe consequences of COVID-19 infection (Renieris et al., 2020) . IL-6 has been proposed as the main proinflammatory mediator involved in the cytokine storm that leads to severe lung injury, respiratory failure and death in COVID-19 patients (Gubernatorova et al., 2020) . Noteworthy, H2S is likely to be an effective down-regulator of IL-6 and an inhibitor of NF-κB pathway (Kodela et al., 2015; Rios et al., 2015) . Generally, the role of H2S in inflammatory response in lung function and disease has been widely studied and emerging evidence highlights that H2S positively correlates with lung function and improves peak expiratory and inspiratory flow rate (Tian et al., 2012) . Both exogenous and endogenous H2S exert beneficial effects in the respiratory system by regulating mucolytic activity. H2S is able to make the mucus less viscous, because it promotes the breakage of mucins via the interaction with disulphide bonds (Costantino et al., 2006) . Furthermore, in human bronchiolar epithelia, H2S triggers an electrolyte absorption through the activation of ATP-sensitive potassium channels (KATP), inhibition of Na + /K + -ATPase and calcium-sensitive potassium channels (Pouokam and Althaus, 2016) . These properties enhance mucociliary clearance, promoting the expulsion of foreign microorganisms. The imbalance of H2S endogenous production is related to pathological processes and progression of several diseases, including hypertension, hypoxic pulmonary hypertension, myocardial injury and viral infection (Chen et al., 2020; Citi et al., 2018; Calderone et al., 2016) . The role of exogenous H2S in lung disease has been studied by administrating H2Sdonor agents; the importance of the "nature" of fast or slow H2S-releasing molecules in inflammatory response predominantly emerged by using molecules able to generate H2S with slow and sustained release kinetics. Indeed, the administration of NaHS, a ''fast releasing'' H2S donor, induced an important inflammatory reaction in mice, underlined by an increased myeloperoxidase (MPO) activity (a marker for tissue leukocyte infiltration) and by the presence of accumulated leukocytes in the lung (Bhatia, 2012) . In contrast, the slow H2Sreleasing compound GYY4137 showed anti-inflammatory activity in vivo, and reduced plasma proinflammatory cytokines (TNF, IL-1β, IL-6) in an experimental model of LPS-induced pulmonary inflammation in rats. Furthermore, GYY4137 treatment was related to a marked antioxidant effect, by restoring the activity of the antioxidant enzymes catalase and superoxide dismutase in lung tissues, and leading to normalization of the balancing between reduced and oxidized glutathione (GSH/GSSG ratio) (Faller et al., 2018) . GYY4137 also inhibited the expression of proinflammatory genes by modulating the activation of nuclear factor NF-кB and interferon regulatory factor 3 (IRF-3) . Mechanistically, Zhang and colleagues revealed that H2S blocks NF-κB pathway activation, in a model of monocrotaline pyrroleinduced inflammatory response in pulmonary artery endothelial cells, through the sulfhydration of IKκβ at Cys179 residue, thus inhibiting IKκβ activity. Such a mechanism of action leads to protective effects in vivo against pulmonary vascular inflammation, vascular remodelling and pulmonary arterial hypertension, suggesting that the post-transcriptional regulation of IKκβ is a novel target of H2S to prevent vascular inflammation (Zhang et al., 2019) . In a mouse model of LPS-induced acute lung injury, GYY4137 prevented lung injury and neutrophil transmigration, by reducing chemoattractant signalling molecules in vitro in endothelial cells and in vivo in lung tissue (Faller et al., 2018) . Indeed, neutrophil infiltration in lungs is a key event in the exacerbation of pulmonary disease associated to COVID-19. Interestingly, H2S modulates the egress of leukocyte, namely neutrophils, from bloodstream to inflamed tissues (Zanardo et al., 2006) and this effect is dependent upon activation of annexin A1 (AnxA1) pro-resolutive pathway (Brancaleone et al., 2014) . Indeed, AnxA1 is exposed to the neutrophil surface and prevent them from transmigration into sub-endothelial region, thus suppressing cytokine production in inflamed tissues (Perretti and D'Acquisto, 2009 ). This mechanism is associated to a reduction of adhesion molecule expression and occurs through the engagement of a specific receptor called formyl-peptide receptor 2 (FPR2) (Dufton et al., 2010) . It is feasible that this overall mechanism operates in lung of COVID-19 patients, where the use of H2S-releasing molecules could limit the passage of leukocytes in the underlying tissue. On one hand, this effect could downregulate the release of cytokines by activated neutrophils and macrophages; on the other hand, the production of growth factors (G-CSF and GM-CSF) responsible for increase in circulating neutrophils could be suppressed, thus embanking the "cytokine storm". It is noteworthy to underline that H2S-donors impair the stability of thrombi formed into the vessels, thus facilitating thrombolysis (Grambow et al., 2017) . This effect has been associated to a reduced formation of platelet-leukocyte aggregates (PLAs), which normally facilitate both leukocyte recruitment and extravasation to sites of inflammation and thrombus formation (Finsterbusch et al., 2018; Badrnya et al., 2014; Diacovo et al., 1996) . In the case of COVID-19 patients, there is a high incidence of coagulative disorders, thus generating a disseminated intravascular coagulation (DIC) being lethal in severe conditions (Marietta et al., 2020) . The possibility to modulate PLAs formation by H2S is therefore of therapeutic interest since PLAs promote both vascular inflammation and coagulation. Indeed, the inhibition of such aggregates, could attenuate in one shot both events and achieve amelioration of patient conditions. Other studies showed that administration of H2S-donors in ovalbumin-treated rats significantly reduced IL-6 and IL-8 and increased anti-inflammatory IL-10 levels in lung and plasma. H2S directly suppressed the proinflammatory response and the production of ROS in neutrophils, underlining the beneficial potential of H2S-releasing compounds in the prophylaxis of acute lung injury. Moreover, H2S promoted anti-inflammatory effects through epigenetic alterations. In particular, it modulated the acetylation and methylation of histones involved in the regulation of proinflammatory factor production and contributed to reduce cytokine release following stimulation with LPS in mice (Faller et al., 2018) . The administration of diallyl disulphide (DADS, a natural H2S slow releasing compound) promoted a protective effect in naphthalene-induced lung injury (Benavides et al., 2007; Martelli et al., 2013) . DADS treatment increased GSH levels in lung tissue, inhibited TNF, IL-6 and IL-8 release, and was associated with suppression of lung inflammatory cell recruitment, in particular neutrophil infiltration (Liu et al., 2018) . SFN, a naturally occurring isothiocyanate able to release H2S expression of multiple antioxidant genes and preventing oxidative damage. Such a mechanism of action has been described also for synthetic isothiocyanates whose H2S-donor profile has been widely described (Prawan et al., 2009; Sestito et al., 2019b; Sestito et al., 2019a; Citi et al., 2019; Martelli et al., 2020a; Martelli et al., 2020b; Testai et al., 2016; Martelli et al., 2014; Citi et al., 2014; Citi et al., 2020a) . Anethole dithiolethione, another H2S-donor, has been widely used as H2S donor or as a moiety for the development of H2S-releasing hybrid drugs, including nonsteroidal anti-inflammatory agents, such as H2S-aspirin and H2S-diclofenac. These novel hybrid drugs have been shown to have better anti-inflammatory effects than the corresponding "parent drugs" aspirin and diclofenac, and the administration of H2S-diclofenac was shown to be more effective in reducing lung MPO activity in a rat model of LPS-induced septic shock, compared with diclofenac alone (Takayama et al., 2011) . (Figure 1 ). The effect of H2S on viral infections represents a promising research field which is presently still poorly investigated. Many pulmonary viral infections promote increase of ROS levels and impairment of antioxidant enzymes, including those associated with the Nrf2-ARE pathway, with consequent reduction of antioxidant response. This leads to hypothesize that agents able to activate the Nrf2 system and induce sustained antioxidant activity may represent a useful strategy to counteract the viral infection by respiratory viruses (Komaravelli and Casola, 2014) . As reported above, many H2S-releasing agents evoke significant protective effects against oxidative stress in the host cells, which are mediated by H2S and/or related sulfane sulfur through well clarified mechanisms, such as increased nuclear translocation of Nrf2 and inhibition of NADPH oxidase enzymes (Gojon and Morales, 2020). Besides the triggering of the "antioxidant machinery" directly attributable to H2S, other "indirect" effects are also involved in antioxidant activity of H2S. For instance, H2S contributes to the maintenance of elevated levels of GSH, which is one of the main intracellular antioxidant compounds and an effective scavenger of reactive species (Gojon and Morales, 2020). GSH can itself be another player with antiviral effects. Indeed, GSH ability to limit viral infections has been long reported. In particular, GSH levels were dramatically reduced after 24 hours of herpes simplex virus type 1 (HSV-1) viral infection; on the other hand, exogenous administration of GSH almost totally abolished HSV-1 replication (Palamara et al., 1995) . BALB/c mice lung and trachea (following intranasal inoculation of mouse-adapted influenza strain A/X-31 virus), showed that GSH reduced viral replication in the in vitro model and viral titer in organs explanted after the in vivo experiments (Cai et al., 2003) . Very recently, GSH was also proposed as a potentially useful agent against SARS-CoV-2, since high-throughput artificial intelligence-based binding affinity prediction indicated a possible GSH interaction with Angiotensin Converting Enzyme 2 (ACE2) or Transmembrane Serine Protease 2 (TMPRSS2), two human proteins closely involved in the process of viral adhesion and entry into the host cell (Kim J, 2020). Some studies reported the potential antiviral effects of organosulfur molecules. However, only subsequent studies have shown that these compounds act as H2S-donors, letting us hypothesize "a posteriori" that the antiviral effect can be linked to the release of this gas. For instance, Fang and colleagues evaluated the effect of diallyl trisulfide (DATS) in cytomegalovirus (CMV)induced hepatitis. In their research, the authors reported that the polysulfide DATS, derived from Allium sativum L., reduced CMV viral load in infected organs in human and mice (Fang et al., 1999; Liu et al., 2004; Liu et al., 2011) been recently described as smart H2S-donors by Calderone and colleagues (Martelli et al., 2014; Citi et al., 2014; Calderone et al., 2016; Marino et al., 2016; Testai et al., 2016; Lucarini et al., 2018; Citi et al., 2019; Martelli et al., 2020b; Martelli et al., 2020a) . In particular, SFN demonstrated antiviral activity against the influenza A/WSN/33 (H1N1) virus by reducing virus replication in vitro using canine kidney cells at low micromolar concentrations (Zhansheng Li1, 2019) . These results seem to find a confirmation in a randomized, doubleblind, placebo controlled clinical study. In this trial, healthy volunteers were treated with SFN or placebo, and received a standard nasal vaccine dose of live attenuated influenza virus. Their peripheral blood immune cell population was analyzed, paying particular attention to natural killer (NK) cells. Blood samples were examined at day 1 (before vaccine dosing) and at day 2 and 21 (after vaccine dosing). The results showed that SFN increased virus-induced granzyme B production by NK cells. Granzyme B is a protease released by NK or T cells in order to induce cell apoptosis, and this increase in granzyme B levels was negatively associated with influenza RNA levels in nasal lavage fluid cells demonstrating again an anti-viral role for SFN (Muller et al., 2016) . Concerning other H2S-donors, some studies were focused on phosphinodithioate GYY4137. GYY4137 is a well-known slow H2S-donor and it was used by the Casola group for a thorough investigation on H2S and its anti-viral activity against respiratory syncytial virus (RSV). Indeed, the researchers observed that the infection with RSV was associated with low levels of CSE mRNA and protein expression in airway epithelial cells, with consequent reduction of H2S generation . Moreover, in RSV-infected CSE knockout mice, they recorded increased viral replication and airway inflammation when compared with wild-type mice (Ivanciuc et al., 2016) . Based on these observations, they used GYY4137 to evaluate the role of H2S on several paramyxovirus infections (RSV, human metapneumovirus and Nipah virus) and recorded a significant reduction of viral replication and of proinflammatory mediator production. The mechanism of GYY4137-induced anti-viral effect is not linked to genome replication nor to the synthesis of viral mRNA or proteins, but to the inhibition of syncytia formation and viral assembly and release. As reported above, GYY4137 showed also anti-inflammatory effects due to regulation of NF-κB and IRF-3 activation after their nuclear translocation . This GYY4137 effect on RSV was also confirmed using in vivo experiments where intranasal administration of GYY4137 to infected mice, within 24 h from infection, inhibited viral replication, reduced proinflammatory mediators and improved airway dysfunction (Ivanciuc et al., 2016) . Recent studies showed that GYY4137 also exhibited similar effects (reduced viral replication and decrease of proinflammatory mediators) in in vitro models using other types of highly pathogenic RNA viruses, such as influenza A and B, Far-Eastern subtype tick-borne flavivirus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus and Ebola virus (Bazhanov et al., 2017b) . Other thiol-activated gem-dithiol-based H2S-donors, while structurally different from GYY4137 yet sharing the ability to release H2S, also induced viral replication inhibition, reduction of proinflammatory mediators and improvement of airways dysfunction both in in vitro and in vivo models. This provides strong evidence to suggest that H2S is the actual player responsible for the observed antiviral effects (Bazhanov et al., 2018) . The antiviral activity of a library of H2S-releasing molecules, together with reference H2Sdonors (e.g., GYY4137, sodium hydrosulfide), was initially tested on pseudotyped Nipah virus (NiV). This preliminary screening showed that most sulfur molecules were endowed with significant effect, and allowed to select a disulfide compound (XM-01) for further evaluation on both enveloped and non-enveloped viral strains, such as RSV, influenza virus (A/WSN/33 strain) and rotavirus. The H2S-releasing effects of XM-01 (a cysteine-based perthiol derivative) were previously reported in a study aimed at identifying cardioprotective H2S-donors (Zhao et al., 2013) . As observed in previous GYY4137 studies, XM-01 exhibited antiviral effects on enveloped viruses. Noteworthy, no activity was observed on non-enveloped viruses (e.g., rotavirus). Thus, as the antiviral action may be due to alterations of the viral membrane, GYY4137 and its analogues could be useful against enveloped viruses at the entry phase of host cell infiltration. However, the author hypothesized that the antiviral activity can also rely on mechanisms other than H2S (Pacheco and Chemistry, 2017) . Finally, in an extremely recent paper it was hypothesized that H2S may also exhibit antiviral activity against SARS-CoV-2 by interfering with ACE2 and TMPRSS2 (Yang, 2020). (Figure 2) . The severity of COVID-19 pandemic is mainly based on two relevant aspects: high degree of contagiousness and high frequency of massive inflammatory reactions, which lead to serious and life-threatening disease outcomes. In this perspective, the pathophysiological role of gasotransmitter H2S provides opportunities for additional investigation. This endogenous mediator can modulate the inflammatory response in a complex regulation of the cytokine cascade; moreover, preliminary studies point to a role of H2S in regulating the host response to viral infections (Yang, 2020). These insights provide a strong case for the potential antiviral benefits that different classes and chemotypes of H2S-donor molecules offer as therapeutics, as recently proposed also by other pioneering hypotheses (Yang, 2020; Evgen'ev and Frenkel, 2020) . Several compounds already in clinical development for other therapeutic indications, Role of hydrogen sulfide in lung inflammation. Hydrogen sulfide shows many beneficial effects in lung inflammation disease. In particular, (A) H2S is able to break mucin disulphide bonds, making the mucus less viscous and easier to be expelled by the respiratory ciliary apparatus, facilitating the elimination of potentially harmful viruses or extraneous particles. (B) H2S blocks NF-κB pathway activation, through the sulfhydration and inhibition of IKKβ enzyme, avoiding the NF-κB translocation into the nucleus, resulting in prevention of the cytokine storm. (C) H2S promotes the activation of Nrf-2, enhancing the expression of antioxidant molecules and enzymes. Moreover H2S is endowed with direct antioxidant activity, thus protecting the tissues from the oxidative stress. (D) Finally, H2S activate KATP channels expressed on the cell membrane of bronchial smooth muscle cells, promoting bronchodilation, and blocks Na + /K + ATPase pump, triggering electrolyte absorption and enhancing mucociliary clearance. Sulfane sulfur -new findings on an old topic A source of hydrogen sulfide and a mechanism of its release in the brain Hydrogen Sulfide Is an Antiviral and Antiinflammatory Endogenous Gasotransmitter in the Airways. Role in Respiratory Syncytial Virus Infection Chemopreventive activity of sulforaphane Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound Respiratory Viral Infections and Subversion of Cellular Antioxidant Defenses Therapeutic options for the 2019 novel coronavirus Role of hydrogen sulfide in paramyxovirus infections Allium sativumderived allitridin inhibits Treg amplification in cytomegalovirus infection Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds Effects of allitridin on acute and chronic mouse cytomegalovirus infection Organic Isothiocyanates as Hydrogen Sulfide Donors Erucin exhibits vasorelaxing effects and antihypertensive activity by H2S-releasing properties Hydrogen sulphide: novel opportunity for drug discovery Pharmacological characterization of the vascular effects of aryl isothiocyanates: is hydrogen sulfide the real player? Cysteine-Activated Releasing Properties and Vascular Effects in Vitro and in Vivo COVID-19: consider cytokine storm syndromes and immunosuppression Protein S-sulfhydration by hydrogen sulfide in cardiovascular system Cystathionine beta-synthase: structure, function, regulation, and location of homocystinuria-causing mutations Effect of Broccoli Sprouts and Live Attenuated Influenza Virus on Peripheral Blood Natural Killer Cells: A Randomized, Double-Blind Study Sulfur-Containing Compounds as Hydrogen Sulfide Donors and Broad-Spectrum Antiviral Agents Evidence for antiviral activity of glutathione: in vitro inhibition of herpes simplex virus type 1 replication Role of cystathionine gammalyase/hydrogen sulfide pathway in cardiovascular disease: a novel therapeutic strategy? Endothelial Dysfunction: Clinical Implications in Cardiovascular Disease and Therapeutic Approaches Annexin A1 and glucocorticoids as effectors of the resolution of inflammation A novel hydrogen sulfide prodrug, SG1002, promotes hydrogen sulfide and nitric oxide bioavailability in heart failure patients This article is protected by copyright. All rights reserved Epithelial Electrolyte Transport Physiology and the Gasotransmitter Hydrogen Sulfide Anti-NF-kappaB and anti-inflammatory activities of synthetic isothiocyanates: effect of chemical structures and cellular signaling Serum Hydrogen Sulfide and Outcome Association in Pneumonia by the SARS-CoV Hydrogen sulfide attenuates cytokine production through the modulation of chromatin remodeling Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Memantine prodrug as a new agent for Alzheimer's Design and synthesis of H2S-donor hybrids: A new treatment for Alzheimer's disease? This article is protected by copyright. All rights reserved 3-Mercaptopyruvate sulfurtransferase produces hydrogen sulfide and bound sulfane sulfur in the brain CII: Pharmacological Modulation of H2S Levels: H2S Donors and H2S Biosynthesis Inhibitors Comparison of the anti-inflammatory and analgesic effects in rats of diclofenacsodium, felbinac and indomethacin patches Inhaled nitric oxide to improve oxygenation for safe critical care transport of adults with severe hypoxemia The novel H2S-donor 4-carboxyphenyl isothiocyanate promotes cardioprotective effects against ischemia/reperfusion injury through activation of mitoKATP channels and reduction of oxidative stress Correlation between serum H2S and pulmonary function in children with bronchial asthma Into the eye of the cytokine storm Sulfur signaling: is the agent sulfide or sulfane? The conversion of H(2)S to sulfane sulfur Up-regulation of IL-6 and TNF-alpha induced by SARS-coronavirus spike protein in murine macrophages via NF-kappaB pathway Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation Endogenous hydrogen sulfide sulfhydrates IKKbeta at cysteine 179 to control pulmonary artery endothelial cell inflammation Natural Sulforaphane From Broccoli Seeds Against Influenza A Virus Replication in MDCK Cells Controllable hydrogen sulfide donors and their activity against myocardial ischemia-reperfusion injury Experimental study on the action of allitridin against human cytomegalovirus in vitro: Inhibitory effects on immediate-early genes